Foundayo has been authorised by the MHRA for weight loss and weight maintenance in the UK, but it is not currently routinely available through the NHS.
NICE guidance for orforglipron is still in development and is currently expected to be published on 18 November 2026. Any future NHS access will depend on the final NICE recommendation, NHS commissioning decisions, local availability and individual eligibility criteria.
Private prescribing is available following a clinical assessment and subject to the medicine being suitable for you.